Search

Introduction and hypothesis: Urinary incontinence (UI) is prevalent among women, including young women (18–30 years old). This article aims to explore the prevalence of UI, as well as toileting behaviors and other factors that are associated with UI, in female college students in central China. Methods: We used convenience sampling to recruit 1000 students from five institutions of higher education. We distributed pencil-and-paper questionnaires to obtain demographic, environmental, and general health information, including whether UI was present or not, and information regarding toileting behaviors used by the respondents. Results: Most students, n = 929, responded to the questionnaire. Their ages ranged from 18 to 26 years old (average: 20.5 ± 1.6); 23.6% of these respondents reported UI, 52.7% often/always worried about public toilet cleanliness, and 25.3% often/always delayed emptying their bladder when they were busy. Respondents who were between 21 and 26 years old had a lower probability of UI (odds ratio [OR] = 0.867 and 95% confidence interval [CI] = 0.771–0.975) than younger respondents (18–21 years old). Respondents who reported constipation (OR = 2.395, 95% CI = 1.494–3.839), drank alcohol (OR = 1.763, 95% CI = 1.114–2.792), often/always delayed urination (OR = 1.738, 95% CI = 1.306–2.313), and/or often/always strained to urinate (OR = 1.433, 95% CI = 1.111–1.849) had greater odds of having UI than respondents who did not have constipation or engage in these behaviors. Conclusions: UI is prevalent in young Chinese women who are attending college. These women should be asked and given culturally appropriate information about UI and associated factors that include toileting behaviors. [ABSTRACT FROM AUTHOR]

Objective: To compare the effect of balanced multielectrolyte solutions(BMES) versus normal saline(NS) for intravenous fluid on chloride levels and clinical outcomes.in patients with predicted severe acute pancreatitis (pSAP)., Summary Background Data: Isotonic crystalloids are recommended for initial fluid therapy in acute pancreatitis, but whether the use of BMES in preference to NS confers clinical benefits is unknown., Methods: In this multicenter, stepped-wedge, cluster-randomized trial, we enrolled patients with pSAP (APACHE II score ≥8 and C-reactive protein >150 mg/L) admitted within 72 hours of the advent of symptoms. The study sites were randomly assigned to staggered start dates for one-way crossover from the NS phase (NS for intravenous fluid) to the BMES phase(Sterofudin for intravenous fluid). The primary endpoint was the serum chloride concentration on trial day3. Secondary endpoints included a composite of clinical and laboratory measures., Results: Overall, 259 patients were enrolled from eleven sites to receive NS(n=147) or BMES(n=112). On trial day3, the mean chloride level was significantly lower in patients who received BMES(101.8 mmol/L(SD4.8) versus 105.8 mmol/L(SD5.9), difference -4.3 mmol/L [95%CI -5.6 to -3.0 mmol/L];P<0.001). For secondary endpoints, patients who received BMES had less systemic inflammatory response syndrome(19/112,17.0% versus 43/147,29.3%, P=0.024) and increased organ failure-free days (3.9 d(SD2.7) versus 3.5days(SD2.7), P<0.001) by trial day7. They also spent more time alive and out of ICU(26.4 d(SD5.2) versus 25.0days(SD6.4), P=0.009) and hospital(19.8 d(SD6.1) versus16.3days(SD7.2), P<0.001) by trial day30., Conclusions: Among patients with pSAP, using BMES in preference to NS resulted in a significantly more physiological serum chloride level, which was associated with multiple clinical benefits(Trial registration number: ChiCTR2100044432)., Competing Interests: Conflict of Interest Disclosures: Pr. Weiqin Li reports consultancy fees and grants from Jiangsu Nhwa Pharmaceuticals. Pr. Lu Ke reports speaker fees from Nhwa Pharmaceuticals. Pr. Jaber reports receiving consulting fees from Drager, Medtronic, Mindray, Fresenius, Baxter, and Fisher & Paykel. Pr. Windsor reports consulting fees and grants from Fisher and Paykel Healthcare and Viatris Ltd. Pr. Bellomo received grants and consultancy fees from Baxter Health Care. The other authors have nothing to declare., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)